Bariatric surgery (BS), especially procedures like Sleeve Gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is the most effective treatment for obesity. Yet, the exact mechanisms governing its effect are somewhat elusive, with current research mainly focusing on post-operative food intake outcomes based on self-reported data, which might not fully capture the nuanced changes in eating behaviours.
To address these gaps, our study plans to employ the newly developed "drinkometer", a device capable of analysing the intricate changes in drinking behaviour following BS. This tool promises to bring a more detailed perspective to the changes in ingestive behaviours, bypassing the inaccuracies of self-reporting methods. By expanding our research to encompass diverse patient demographics and examining potential links to physiological shifts like gut hormone level alterations, the study aims to provide a more rounded understanding of the long-term impacts of BS on eating behaviours.
Age ≥ 18 year
BMI ≥ 35 kg/m2 for patients with planned RYGB or SG operation
BMI ≥ 30 kg/m2 for external controls affected by obesity but no planned RYGB or SG within the next 12 months, and
BMI ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 for controls without obesity.
history of previous bariatric operations and/ or revisional surgery (e.g., alteration of limb lengths after primary RYGB),
smoking,
established diagnosis of type 1 or 2 diabetes mellitus, and
polycystic ovary syndrome (PCOS).
8
Treatment groupsSee each treatment group below.
University of Zurich
Lead sponsor
Florida State University
Collaborator
University College Dublin
Collaborator